Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Cirrhosis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Cirrhosis
    Liver Transplant Outcomes Similar for Patients With Nonalcoholic vs Alcoholic Cirrhosis - (DGNews)
    TopAbstracts in Cirrhosis 11/17/2009 - (DGNews)
    Satavaptan Shows Poor Survival, Despite Modest Effectiveness in the Management of Recurrent Ascites: Presented at AASLD - (DGDispatch)
    Viral Load Predicts Outcome of Liver Transplant Recipients With Hepatitis C: Presented at AASLD - (DGDispatch)
    Rifaximin Protects Patients With Cirrhosis From Breakthrough Hepatic Encephalopathy Over Long Term: Presented at AASLD - (DGDispatch)

    News archive

     Recent webcasts/CME - Cirrhosis

    Webcasts/CME archive

     Recent cases - Cirrhosis
      Incisional Hernia as an Unusual Cause of Hepatic Encephalopathy in a 62-Year-Old Man with Cirrhosis: A Case Report
      Gefitinib for Non-Small Cell Lung Cancer Patients with Liver Cirrhosis
      Intra-Hepatic Splenosis as an Unexpected Cause of a Focal Liver Lesion in a Patient with Hepatitis C and Liver Cirrhosis: A Case Report
      Black Esophagus
      A Case of Non-O1 and Non-O139 Vibrio cholerae Septicemia with Endophthalmitis in a Cirrhotic Patient

      Cases archive
        




      my personal edition > cirrhosis > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Carvedilol May Offer Therapeutic Potential In Cirrhosis

      A DGReview of :"Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis."
      Hepatology

      12/17/2002
      By David Loshak


      Carvedilol has a greater portal hypotensive effect than does propranolol in patients with cirrhosis. However, the its systemic hypotensive effects may limit its clinical applicability.

      Investigators in Barcelona and Madrid, Spain, noted that while short-term carvedilol was more powerful than propranolol in reducing hepatic venous pressure gradient in cirrhotic patients, it induced arterial hypotension. That might prevent its long-term use in portal hypertensive patients, the investigators suggested.

      To compare hepatic venous pressure gradient reduction and safety of the two drugs long-term, the researchers randomised 51 cirrhotic patients to receive either carvedilol (n=26) or propranolol (n=25).

      Haemodynamic measurements and renal function were assessed at baseline and after 11.1 ± 4.1 weeks.

      Carvedilol lowered the hepatic venous pressure gradient by 19 ± 2.0 percent. This was significantly more than propranolol (12 ± 2.0 percent).

      More than half (54 percent) of patients given carvedilol achieved hepatic venous pressure gradient reductions of 20 percent or more or of 12 mm Hg or less. Fewer than a quarter (23 percent) of propranolol recipients achieved such reductions.

      Carvedilol caused a statistically significant decrease (11 ± 1.0 percent) in mean arterial pressure whereas the decrease with propranolol was not significant (5 ± 3.0 percent).

      Carvedilol also led to statistically significant increases in plasma volume (11 ± 5.0 percent) and body weight (2 .0± 1.0 percent).

      Glomerular filtration rate did not change with either drug. The dose of diuretics was increased more often after carvedilol (27 percent) than after propranolol (8.0 percent). Adverse events caused two patients receiving carvedilol and three patients receiving propranolol to discontinue treatment.

      The investigators said that further trials were needed to confirm carvedilol's therapeutic potential.
      Hepatology 2002;36(6):1367-1373. "Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis."

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send